CX3CL1 and Parkinson disease: In spite of these observations, several publications deal with the neurotoxic effect of fractalkine in many models of chronic neurodegenerative disorders, e.g. Alzheimer’s disease and Parkinson’s disease (Liu et al. 2010; Shan et al. 2011).